Key Points
- Director Jeanne Thoma sold 1,000 ANI Pharmaceuticals shares at an average price of $71.53, totaling $71,530. The Rule 10b5-1 transaction reduced her holdings by 3.6% to 26,762 shares.
- ANI Pharmaceuticals reported quarterly revenue of $266.04 million and EPS of $2.21, exceeding analyst estimates, while revenue increased 25.8% year over year.
- Analysts maintain a “Moderate Buy” consensus with an average price target of $105.57, despite some recent target reductions and a stock price near its 52-week low.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) VP Meredith Cook sold 500 shares of ANI Pharmaceuticals stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $70.79, for a total value of $35,395.00. Following the completion of the transaction, the vice president directly owned 73,924 shares in the company, valued at $5,233,079.96. This represents a 0.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Meredith Cook also recently made the following trade(s):
- On Thursday, August 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $75.48, for a total transaction of $37,740.00.
- On Monday, July 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $81.84, for a total transaction of $40,920.00.
ANI Pharmaceuticals Stock Performance
Shares of ANIP stock opened at $70.40 on Tuesday. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99. The company has a market cap of $1.62 billion, a PE ratio of 15.17 and a beta of 0.45. The company's fifty day simple moving average is $76.97 and its 200-day simple moving average is $78.17. ANI Pharmaceuticals, Inc. has a 52 week low of $69.58 and a 52 week high of $99.39.
ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The firm had revenue of $266.04 million during the quarter, compared to the consensus estimate of $260.13 million. During the same period in the prior year, the firm earned $1.80 EPS. The firm's quarterly revenue was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities research analysts anticipate that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current year.
Institutional Investors Weigh In On ANI Pharmaceuticals
A number of institutional investors and hedge funds have recently bought and sold shares of ANIP. Tidal Investments LLC acquired a new position in shares of ANI Pharmaceuticals in the 2nd quarter worth $248,000. WINTON GROUP Ltd acquired a new stake in shares of ANI Pharmaceuticals in the second quarter worth about $4,558,000. Corient Private Wealth LP raised its position in shares of ANI Pharmaceuticals by 95.2% in the second quarter. Corient Private Wealth LP now owns 24,106 shares of the specialty pharmaceutical company's stock valued at $1,995,000 after purchasing an additional 11,754 shares during the period. Amundi lifted its position in ANI Pharmaceuticals by 595.5% during the 2nd quarter. Amundi now owns 31,793 shares of the specialty pharmaceutical company's stock worth $2,632,000 after acquiring an additional 27,222 shares during the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of ANI Pharmaceuticals during the 2nd quarter worth about $1,449,000. 76.05% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several equities research analysts recently commented on ANIP shares. Weiss Ratings downgraded ANI Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a report on Tuesday, August 11th. Wall Street Zen downgraded shares of ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 8th. Canaccord Genuity Group reduced their target price on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating on the stock in a research report on Monday, August 10th. Leerink Partners started coverage on shares of ANI Pharmaceuticals in a report on Wednesday, September 9th. They set an "outperform" rating and a $104.00 price target for the company. Finally, Guggenheim dropped their price target on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a "buy" rating on the stock in a research note on Monday, August 10th. Five investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $105.57.
Read Our Latest Research Report on ANIP
About ANI Pharmaceuticals
(
Get Free Report)
ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with complex formulations, manufacturing requirements or specialized commercial opportunities, and serves a range of therapeutic areas.
ANI's portfolio includes Cortrophin-Zinc, a repository corticotropin injection used for certain autoimmune and inflammatory conditions, along with a selection of branded and generic medicines.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
